Rapid CommunicationCardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19)Dixon, Dave L. PharmD*,†; Van Tassell, Benjamin W. PharmD*,†; Vecchié, Alessandra MD†; Bonaventura, Aldo MD†,‡; Talasaz, Azita H. PharmD, PhD§; Kakavand, Hessam PharmD§; D'Ascenzo, Fabrizio MD¶; Perciaccante, Antonio MD║; Castagno, Davide MD, PhD¶; Ammirati, Enrico MD, PhD**; Biondi-Zoccai, Giuseppe MD††,‡‡; Stevens, Michael P. MD, MPH§§; Abbate, Antonio MD, PhD†Author Information *Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA; †Division of Cardiology, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA; ‡Department of Internal Medicine, First Clinic of Internal Medicine, University of Genoa, Genoa, Italy; §Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran; ¶Division of Cardiology, Department of Medical Science, University of Turin, Turin, Italy; ║Department of Medicine, University Health Agency Giuliano Isontina, “San Giovanni di Dio” Hospital, Gorizia, Italy; **Department of Cardiology, Niguarda Hospital, Milan, Italy; ††Department of Medico-Surgical Sciences and Biotechnologies Sapienza', University of Rome, Rome, Italy; ‡‡Mediterranea Cardiocentro, Napoli, Italy; and §§Division of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA. Reprints: Dave L. Dixon, PharmD, Virginia Commonwealth University School of Pharmacy, 410 N. 12th St, Box 980533, Richmond, VA 23298-0533 (e-mail: firstname.lastname@example.org). The authors report no conflicts of interest. Received March 26, 2020 Accepted March 30, 2020 Journal of Cardiovascular Pharmacology: May 2020 - Volume 75 - Issue 5 - p 359-367 doi: 10.1097/FJC.0000000000000836 Buy Metrics Abstract A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequelae, such as myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.